겸상 적혈구증 치료 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of sickle cell disease (SCD) treatment Market

The global sickle cell disease (SCD) treatment market was valued at USD 3.94 billion in 2025 and increased to USD 4.73 billion in 2026, with projections indicating it will reach USD 20.47 billion by 2034. The market is experiencing strong growth due to rising disease prevalence, increasing awareness, and advancements in treatment options. The United States dominated the market with a 63.35% share in 2025, supported by strong healthcare infrastructure, high diagnosis rates, and continuous drug development initiatives.

Sickle cell disease is a genetic blood disorder that affects hemoglobin, leading to abnormal red blood cells, reduced oxygen flow, and complications such as anemia, pain crises, and organ damage. Treatment approaches include blood transfusion, pharmacotherapy, and bone marrow transplantation, with increasing focus on advanced therapies.

Market Trends

One of the most significant trends in the market is the growing adoption of gene therapy. Gene therapy targets the root cause of the disease by correcting genetic mutations, offering the potential for long-term or permanent treatment. Several clinical trials, including CRISPR-based therapies, are progressing and showing promising outcomes.

Another key trend is the increasing focus on innovative drug development. Pharmaceutical companies are investing heavily in research and development to introduce new therapies that reduce complications such as vaso-occlusive crises (VOCs). Recently approved drugs and pipeline candidates are expected to transform treatment standards.

Additionally, there is a rising emphasis on personalized medicine and targeted therapies, which aim to improve patient outcomes and reduce treatment-related complications.

Driving Factors

The market is primarily driven by the increasing prevalence of sickle cell disease globally. According to estimates, millions of individuals are affected worldwide, with a significant patient population in regions such as Africa, the U.S., and India. In the U.S. alone, approximately 100,000 individuals are affected by SCD.

Another major driver is the growing severity and frequency of disease complications, such as vaso-occlusive crises. Patients can experience multiple episodes annually, increasing the demand for effective treatment solutions and emergency care.

The introduction of novel therapies and regulatory support is also accelerating market growth. Agencies such as the U.S. FDA and European Medicines Agency are providing fast-track approvals for innovative drugs, encouraging pharmaceutical companies to expand their product pipelines.

Furthermore, increasing awareness and government initiatives aimed at improving diagnosis and treatment access are contributing to market expansion.

Restraining Factors

Despite strong growth prospects, the market faces challenges due to the limited availability of treatment options in developing regions. Many countries lack access to advanced therapies and essential medications such as hydroxyurea.

Another major restraint is the high cost of treatment, particularly for advanced therapies such as gene therapy and bone marrow transplantation, which limits accessibility for a large patient population.

Additionally, lack of awareness and inadequate healthcare infrastructure in certain regions continue to hinder market growth.

Segmentation Analysis

By treatment modality, the market is segmented into blood transfusion, bone marrow transplant, and pharmacotherapy. The blood transfusion segment holds the largest share due to its effectiveness in managing severe complications such as stroke. However, pharmacotherapy is expected to grow rapidly due to the introduction of new drugs and increasing adoption of advanced treatments.

By end-user, the market includes hospitals, specialty clinics, and others. Hospitals dominate the segment due to the high number of patient admissions and availability of advanced treatment facilities. Specialty clinics are also gaining traction due to specialized care and increasing patient preference.

Regional Analysis

The United States leads the global market with a valuation of USD 2.49 billion in 2025 and USD 3.00 billion in 2026, driven by strong research activities, high treatment accessibility, and continuous product approvals.

Europe holds a significant share, supported by favorable reimbursement policies and increasing patient awareness. Countries in the region are focusing on expanding treatment accessibility and improving healthcare infrastructure.

The Middle East & Africa region is expected to witness notable growth due to the high prevalence of SCD and increasing awareness initiatives. However, limited healthcare resources remain a challenge.

Key Industry Players and Developments

Major players in the market include Pfizer Inc. (Global Blood Therapeutics), Novartis AG, Emmaus Medical, bluebird bio Inc., Agios Pharmaceuticals, and Bristol-Myers Squibb Company. These companies are focusing on developing innovative therapies and expanding their global presence.

Recent developments include strategic partnerships, product approvals, and expansion programs aimed at improving treatment accessibility and addressing unmet medical needs.

Conclusion

The sickle cell disease treatment market is projected to grow from USD 3.94 billion in 2025 to USD 20.47 billion by 2034, driven by rising disease prevalence, advancements in gene therapy, and increasing investment in drug development. While challenges such as high treatment costs and limited access in developing regions persist, ongoing innovation and regulatory support are expected to significantly transform the treatment landscape in the coming years.

Segmentation By Treatment Modality, End-user, and Geography

By Treatment Modality * Bone Marrow Transplant

• Blood Transfusion
• Pharmacotherapy
  • Hydroxyurea
  • Branded Products
• Endari
• Adakveo
• Oxbryta
• Zynteglo
• PYRUKYND (Mitapivat)
• CTX001
• Inclacumab
• MGTA-145
• Vamifeport (VIT-2763)
• ALXN1820
• FT-4202
• GBT021601

By End-user

Hospitals

• Specialty Clinics
• Others

By Geography * U.S. (By Treatment Modality and End-user)

• Europe (By Treatment Modality, End-user, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Rest of the World (By Treatment Modality, End-user, and Country/Sub-region)
  • India
  • China
  • Japan
  • GCC Countries
  • Rest of ROW

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Sickle Cell Disease, For Key Countries/ Regions, 2025
• 4.2. Overview - Branded Drugs (Marketed)
• 4.3. Pipeline Analysis, Key Players
• 4.4. New Product Launches
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
• 4.6. Impact of COVID-19 on the Market

5. Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Treatment Modality
  • 5.1.1. Bone Marrow Transplant
  • 5.1.2. Blood Transfusion
  • 5.1.3. Pharmacotherapy
    • 5.1.3.1. Hydroxyurea
    • 5.1.3.2. Branded Products
      • 5.1.3.2.1. Endari
      • 5.1.3.2.2. Adakveo
      • 5.1.3.2.3. Oxbryta
      • 5.1.3.2.4. PYRUKYND (Mitapivat)
      • 5.1.3.2.5. Zynteglo
      • 5.1.3.2.6. CTX001
      • 5.1.3.2.7. Inclacumab
      • 5.1.3.2.8. Vamifeport (VIT-2763)
      • 5.1.3.2.9. ALXN1820
      • 5.1.3.2.10. MGTA-145
      • 5.1.3.2.11. FT-4202
      • 5.1.3.2.12. GBT021601
• 5.2. Market Analysis, Insights and Forecast - By End-user
  • 5.2.1. Hospitals
  • 5.2.2. Specialty Clinics
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Country/Region
  • 5.3.1. U.S.
  • 5.3.2. Europe
  • 5.3.3. Rest of the World

6. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Treatment Modality
  • 6.1.1. Bone Marrow Transplant
  • 6.1.2. Blood Transfusion
  • 6.1.3. Pharmacotherapy
    • 6.1.3.1. Hydroxyurea
    • 6.1.3.2. Branded Products
      • 6.1.3.2.1. Endari
      • 6.1.3.2.2. Adakveo
      • 6.1.3.2.3. Oxbryta
      • 6.1.3.2.4. PYRUKYND (Mitapivat)
      • 6.1.3.2.5. Zynteglo
      • 6.1.3.2.6. CTX001
      • 6.1.3.2.7. Inclacumab
      • 6.1.3.2.8. Vamifeport (VIT-2763)
      • 6.1.3.2.9. ALXN1820
      • 6.1.3.2.10. MGTA-145
      • 6.1.3.2.11. FT-4202
      • 6.1.3.2.12. GBT021601
• 6.2. Market Analysis, Insights and Forecast - By End-user
  • 6.2.1. Hospitals
  • 6.2.2. Specialty Clinics
  • 6.2.3. Others

7. Europe Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Treatment Modality
  • 7.1.1. Bone Marrow Transplant
  • 7.1.2. Blood Transfusion
  • 7.1.3. Pharmacotherapy
    • 7.1.3.1. Hydroxyurea
    • 7.1.3.2. Branded Products
      • 7.1.3.2.1. Endari
      • 7.1.3.2.2. Adakveo
      • 7.1.3.2.3. Oxbryta
      • 7.1.3.2.4. PYRUKYND (Mitapivat)
      • 7.1.3.2.5. Zynteglo
      • 7.1.3.2.6. CTX001
      • 7.1.3.2.7. Inclacumab
      • 7.1.3.2.8. Vamifeport (VIT-2763)
      • 7.1.3.2.9. ALXN1820
      • 7.1.3.2.10. MGTA-145
      • 7.1.3.2.11. FT-4202
      • 7.1.3.2.12. GBT021601
• 7.2. Market Analysis, Insights and Forecast - By End-user
  • 7.2.1. Hospitals
  • 7.2.2. Specialty Clinics
  • 7.2.3. Others

8. Rest of the World Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Treatment Modality
  • 8.1.1. Bone Marrow Transplant
  • 8.1.2. Blood Transfusion
  • 8.1.3. Pharmacotherapy
    • 8.1.3.1. Hydroxyurea
    • 8.1.3.2. Branded Products
      • 8.1.3.2.1. Endari
      • 8.1.3.2.2. Adakveo
      • 8.1.3.2.3. Oxbryta
      • 8.1.3.2.4. PYRUKYND (Mitapivat)
      • 8.1.3.2.5. Zynteglo
      • 8.1.3.2.6. CTX001
      • 8.1.3.2.7. Inclacumab
      • 8.1.3.2.8. Vamifeport (VIT-2763)
      • 8.1.3.2.9. ALXN1820
      • 8.1.3.2.10. MGTA-145
      • 8.1.3.2.11. FT-4202
      • 8.1.3.2.12. GBT021601
• 8.2. Market Analysis, Insights and Forecast - By End-user
  • 8.2.1. Hospitals
  • 8.2.2. Specialty Clinics
  • 8.2.3. Others

9. Competitive Analysis

• 9.1. Global Market Share Analysis (2025)
• 9.2. Company Profiles
  • 9.2.1. Bristol-Myers Squibb Company
    • 9.2.1.1. Overview
    • 9.2.1.2. Product
    • 9.2.1.3. SWOT Analysis
    • 9.2.1.4. Recent Developments
    • 9.2.1.5. Strategies
    • 9.2.1.6. financials (Based on Availability)
  • 9.2.2. Addmedica
    • 9.2.2.1. Overview
    • 9.2.2.2. Product
    • 9.2.2.3. SWOT Analysis
    • 9.2.2.4. Recent Developments
    • 9.2.2.5. Strategies
    • 9.2.2.6. financials (Based on Availability)
  • 9.2.3. Novartis AG
    • 9.2.3.1. Overview
    • 9.2.3.2. Product
    • 9.2.3.3. SWOT Analysis
    • 9.2.3.4. Recent Developments
    • 9.2.3.5. Strategies
    • 9.2.3.6. financials (Based on Availability)
  • 9.2.4. Global Blood Therapeutics, Inc. (Pfizer Inc.)
    • 9.2.4.1. Overview
    • 9.2.4.2. Product
    • 9.2.4.3. SWOT Analysis
    • 9.2.4.4. Recent Developments
    • 9.2.4.5. Strategies
    • 9.2.4.6. financials (Based on Availability)
  • 9.2.5. Emmaus Medical, Inc.
    • 9.2.5.1. Overview
    • 9.2.5.2. Product
    • 9.2.5.3. SWOT Analysis
    • 9.2.5.4. Recent Developments
    • 9.2.5.5. Strategies
    • 9.2.5.6. financials (Based on Availability)
  • 9.2.6. bluebird bio Inc.
    • 9.2.6.1. Overview
    • 9.2.6.2. Product
    • 9.2.6.3. SWOT Analysis
    • 9.2.6.4. Recent Developments
    • 9.2.6.5. Strategies
    • 9.2.6.6. financials (Based on Availability)
  • 9.2.7. Agios Pharmaceuticals, Inc.
    • 9.2.7.1. Overview
    • 9.2.7.2. Product
    • 9.2.7.3. SWOT Analysis
    • 9.2.7.4. Recent Developments
    • 9.2.7.5. Strategies
    • 9.2.7.6. financials (Based on Availability)